 Home > Medical News > Latest Medical News > Unexplained hepatitis in many countries may exacerbate the supply of raw materials such as Huang Baiyin Chen!

Unexplained hepatitis in many countries may exacerbate the supply of raw materials such as Huang Baiyin Chen!

 Last Update: 2022-05-13
 Source: Internet
 Author: User

Tags

carpet grass

healthy food eat

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, cases of acute hepatitis of unknown etiology in children have continued to appear in countries around the world.
From April 15 announced by WHO to April 28, a total of 16 countries have reported more than 180 cases of acute hepatitis of unknown etiology in children.
The countries reporting these cases are from In Europe, the Americas and the Western Pacific Region, the majority of cases are younger than 10 years of age, and many are younger than 5 years of age
.

Moreover, 3 countries indicated that the background rate of this unexplained acute hepatitis in children was significantly higher than expected (according to the official website of the US National Center for Biotechnology Information, the background rate is used to calculate the established population and population in the absence of interventions such as vaccines).
The expected number of cases of an adverse event, such as a heart attack, in a time period
.
)

WHO medical experts said in an interview with media reporters that every year there are reports of cases of childhood hepatitis of unknown etiology, but this year it has caused concern because no reported cases of hepatitis of unknown etiology have been found to cause childhood hepatitis.
Common causes, including infectious and noninfectious causes
.
Also, hepatitis of unknown etiology occurs mainly in previously healthy children
.

Compared with the public's concern about acute hepatitis cases in children with unknown causes, our platform is more concerned about the supply of raw materials of traditional Chinese medicines commonly used in hepatitis, such as Yin Chen and Tian Jihuang .
The following is an analysis of the supply of raw materials of traditional Chinese medicines commonly used to treat hepatitis:

　　1.
Analysis of the formula

　　Table 1: Chinese patent medicines and prescriptions commonly used in clinical diagnosis and treatment of hepatitis in China (Data source: State Food and Drug Administration)

　　Figure 1: Raw material cost of 6 kinds of traditional Chinese patent medicines commonly used in clinical practice from 2019.
01 to 2022.
04 (unit: yuan/dose)

　　From the perspective of raw material costs: the general increase in Chinese herbal medicines in 2021 will lead to rising production costs of proprietary Chinese medicines
.
From 2019 to 2020, although the production cost has been adjusted, the cost of raw materials has begun to increase significantly in the context of the general increase in Chinese medicinal materials in 2021
.
From January 2021 to April 2022, the cost of feeding for Jigucaogan Pills, Sanbaicaogan Granules, Yinbaigan Granules, Fufanggan Granules, Xiaoergan Granules, Gankangfu Pills, and Jaundice Ganwan Pills increased by 19.
27% and 19.
27% respectively.
10.
69%, 25.
00%, 12.
35%, 26.
58%, 30.
95% and 41.
13%
.

　　In 2021, in the context of the general increase in raw materials, the market prices of some inconspicuous varieties such as Zelan, Yinchen, Phellodendron, Cyanophora, Liu Jinu, and Gardenia will also rise rapidly, constantly driving up the cost of raw materials
.
Especially low-priced varieties such as Zelan, Yinchen, Yujin, Liu Jinu, Hawthorn and other varieties, due to the rapid reduction in production, there will be a shortage of resources in 2021
.

　　2.
Analysis of the growth cycle: varieties with short cycles account for a high proportion, and the market changes greatly

　　Table 2: The growth cycle of 6 Chinese patent medicines involving Chinese herbal medicines

　　Figure 2: Proportion of the growth cycle of raw material varieties

　　From the perspective of growth cycle: the proportion of varieties with short growth cycle is as high as 71.
43%
.
There are 35 varieties of raw materials involved in the 6 kinds of proprietary Chinese medicines, of which 20 are 1-year-old varieties (see Table 2), accounting for 57.
14%; 5 are 2-year-old varieties, accounting for 14.
29%; 7 are 3-year-old varieties, accounting for 20.
00%; There are 5-year-old, 7-year-old and 8-year-old varieties each, accounting for 8.
57% in total
.

　　Figure 3: 2021.
01-2022.
04 35 kinds of raw material market fluctuations

　　Judging from the ups and downs of the market: the high proportion of price-raising varieties has led to continuously high production costs
.
Among the 35 raw material varieties, the rising varieties are Zelan, Baishao, Yinchen, Citrus aurantium, Treats, Corydalis, Cyanophora, Angelica, Bergamot, Turmeric, Tian Jihuang, Liu Jinu, Gardenia, Chrysanthemum, Hawthorn, Salvia miltiorrhiza, Banlangen, Tongcao, Poria, Bupleurum, Rhizoma Imperatae, Green Bark, and Money Grass, a total of 23, accounting for 65.
71%; the same varieties of soybean yellow roll, talc, chicken bone grass, green leaf gall, gangren root, licorice, fistula Ginseng, Sanbaicao, Yingbubo totaled 9, accounting for 25.
71%; betel nut, dandelion, skullcap totaled 3, accounting for 8.
57%
.

　　Among them, the prices of Zelan, Yinchen, Citrus aurantium, Treats, Corydalis, Cyanophora, Bergamot, and Turmeric all rose by more than 50%
.

　　3.
Analysis of raw materials: The overall market before the new production in 2022 is still moving forward with shocks, and the market will gradually adjust after the new production.

　　Zeeland: The market has been in a downturn for 5 years.
Production in various production areas has been severely reduced, and social inventory has been fully digested
.
After the new production in 2021, the shortage of production and sales is prominent, and the market has ushered in a rapid rise
.

　　The current market price is very tempting for growers.
Due to the low difficulty of planting Zelan and the short growth cycle, the market will remain at a high level before the new production in 2022, and the overall market will adjust after the new production
.

　　Yin Chen: From 2018 to 2019, the market has ushered in a slight decline.
Due to the continuous impact of market prices on production costs, the enthusiasm of farmers in production areas for planting has been severely frustrated
.
In the case of rapid shrinking of production and slight growth of market demand, the market has rebounded significantly
.
In addition, since 2012, affected by the rising labor costs, the overall market of this variety has been in a continuous upward channel
.

　　Although the current price is attractive to growers, their willingness to plant is not strong.
Therefore, before the new production in 2022, the overall market is still running at a high level, and the market will remain at 7-10 after the new production.
Yuan (kg price, the same below) fluctuated
.

　　Xiangfu: The market has entered a downward channel since 2010.
The declining market price has continuously impacted production costs, resulting in a serious setback in planting enthusiasm in various production areas.
In addition, due to the impact of climate in 2021, the yield per unit of Xiangfu is generally lower than in previous years
.
Under the influence of severe production cuts and lower unit yields, the market has risen rapidly
.

　　The current price is very tempting for growers.
In addition, this variety is less difficult to plant and easy to manage in production.
This year, the market will continue to fluctuate before the new production, and the overall market will be significantly adjusted after the new production
.

　　Tian Jihuang: The market has entered a downward channel since 2016, and the market price has continued to bottom out, impacting production costs
.

　　Because the social demand for this variety is not large, and the production and planting are mainly in old production areas, although the price of this variety has risen significantly, it is not very attractive to farmers, and labor costs are also rising.
The market will remain in a shock run of 13-17 yuan
.

　　V.
Summary

　　1.
The number of people suffering from hepatitis is relatively large, and the attention of Chinese patent medicines for anti-hepatitis will increase.
In 2017, WHO has listed hepatitis as one of the important threats to global public health
.
Data in recent years shows that nearly 100 million people in China are infected with hepatitis B or hepatitis C virus.
More than 90% of liver cancer in China is related to viral hepatitis, and more than 400,000 patients die of liver cancer every year.
Therefore, the demand for hepatitis drugs is still huge.

.
The emergence of acute hepatitis in children of unknown cause in the world will increase the attention of Chinese patent medicine for hepatitis
.

　　2.
At present, the cost of Chinese patent medicines is rising, and the raw materials of traditional Chinese medicines for hepatitis are running at a high level before production.
The skyrocketing prices of raw materials of traditional Chinese medicines directly lead to the continuous increase of production costs of enterprises .
Through analysis, it can be seen that the overall situation of raw materials of traditional Chinese medicines for hepatitis will remain high before production.
run high
.
After the new production, with the timely replenishment of raw materials, the production cost of the enterprise has also been alleviated to a certain extent
.

　　3.
Focus on the guaranteed supply of raw materials from semi-wild sources such as Yin Chen.
Since last year, the supply of hepatitis-related Chinese patent medicine raw materials, especially the semi-wild Chinese medicinal materials, has continued to be tight, and prices have continued to rise, such as Cork, Yin Chen, Yujin, etc.

.
Unexplained hepatitis cases in the world may once again stimulate the growth of raw material consumption and exacerbate the current tight supply situation.
Enterprises and medical institutions have to guard against it
.

　　 (Unless otherwise stated in the text, the data are all from the big data of the pharmaceutical industry in Tiandi Yuntu)